pubmed.ncbi.nlm.nih.gov

Ustekinumab for the treatment of Crohn's disease - PubMed

Review

Ustekinumab for the treatment of Crohn's disease

Reena Khanna et al. Immunotherapy. 2013 Aug.

Abstract

Crohn's disease (CD) results from a pathological immune response to luminal antigens in genetically predisposed individuals. Since the causes of CD are complex and only partially understood, treatment is based on the empiric use of anti-inflammatory drugs. Although multiple therapies for CD currently exist, a substantial proportion of patients are unresponsive to conventional agents. Approximately a third of patients fail treatment with TNF antagonists, and up to 40% of patients who initially benefit subsequently lose response. Accordingly, new approaches are required. Ustekinumab, a fully human IgG1-κ monoclonal antibody to the p40 subunit shared by IL-12 and IL-23, has emerged as a promising new treatment for both psoriasis and CD. This article reviews the available data regarding the mechanism of action, pharmacokinetics, efficacy and safety of ustekinumab in CD.

PubMed Disclaimer

Cited by

Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease.
Wang H, Chao K, Ng SC, Bai AH, Yu Q, Yu J, Li M, Cui Y, Chen M, Hu JF, Zhang S. Wang H, et al. Genome Biol. 2016 Mar 30;17:58. doi: 10.1186/s13059-016-0901-8. Genome Biol. 2016. PMID: 27029486 Free PMC article.
A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides.
Geng S, Chang H, Qin W, Lv M, Li Y, Feng J, Shen B. Geng S, et al. Immunol Res. 2015 Jul;62(3):377-85. doi: 10.1007/s12026-015-8667-8. Immunol Res. 2015. PMID: 26059602
Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives.
Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Tontini GE, et al. World J Gastroenterol. 2015 Jan 7;21(1):21-46. doi: 10.3748/wjg.v21.i1.21. World J Gastroenterol. 2015. PMID: 25574078 Free PMC article. Review.
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK, Nguyen TM, Khanna R, Timmer A. MacDonald JK, et al. Cochrane Database Syst Rev. 2016 Nov 25;11(11):CD007572. doi: 10.1002/14651858.CD007572.pub3. Cochrane Database Syst Rev. 2016. PMID: 27885650 Free PMC article. Review.
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P, Loftus EV Jr. Deepak P, et al. Drug Des Devel Ther. 2016 Nov 11;10:3685-3698. doi: 10.2147/DDDT.S102141. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27956825 Free PMC article. Review.

Ustekinumab for the treatment of Crohn's disease - PubMed